Core Viewpoint - The company emphasizes the potential of robotics in the medical field, highlighting improvements in effectiveness, efficiency, and cost reduction, while maintaining that expert operation and patient-centered ethics are paramount [1] Group 1: Technological Advancements - The rapid development of technology is paving the way for significant advancements in medical robotics [1] - The introduction of the new generation of robotic equipment, such as the Zeiss VISUMAX800 and the SMILEpro, is planned for multiple hospitals by 2025 [1] Group 2: Operational Milestones - The Changsha Medical Center successfully performed Hunan Province's first eye surgery using a robotic-assisted technique for precise subretinal injection [1]

Core Viewpoint - The Tai'an Tongyi Ren Ophthalmology Hospital has been fined for violating medical insurance regulations, including duplicate charges and improper billing practices [1][2]. Summary by Relevant Categories Administrative Penalty - The Tai'an Medical Security Bureau issued an administrative penalty decision (Document No. Tai'an Medical Insurance Office [2025] No. 8) against the hospital [2]. - The penalty includes a fine of 39,399.48 yuan (approximately 3.94 million yuan) [1][2]. - The penalty decision date is set for December 31, 2025 [2]. Violations - The hospital was found to have engaged in multiple illegal activities, including: - Duplicate charging - Charging above standard rates - Switching diagnostic treatment items - Including non-reimbursable medical expenses in the medical insurance fund settlement [1][2]. - These actions violate the "Regulations on the Supervision and Administration of the Use of Medical Insurance Funds" [2]. Legal Basis - The penalty was based on Article 38 of the "Regulations on the Supervision and Administration of the Use of Medical Insurance Funds" and the "Shandong Province Medical Insurance Administrative Penalty Discretionary Guidelines" [2].

1月11日，深圳普瑞眼科（301239）医院举办"高清视界，不分昼夜——EVO+ ICL(V5)新品发布会"。作 为瑞士STAAR Surgical公司认证的中国内地首批EVO+ ICL(V5)临床应用合作中心，深圳普瑞眼科不仅 带来了前沿晶体技术，更展现了由"双院长、双博导"领衔的中山眼科博士团的医疗实力。 中山眼科博士团护航新技术落地 作为博士团核心成员，徐洋涛团队已于发布会前夕成功实施了院内首批EVO+ ICL(V5)晶体植入手术， 手术效果备受好评。 6.1mm大光区，直击"夜视"痛点 徐洋涛在现场解析了V5晶体的核心突破——中央光学区扩大至6.1mm。这一设计如同给眼睛换上了"更 大的镜头"，有效覆盖暗光下自然放大的瞳孔。这对视觉质量有极高要求的群体尤为重要。 发布会当天，两个不同阶段的患者分别分享术前、术后体验，全方位展示V5技术的落地全貌。王同学 是一位高校学霸，"因为经常需要熬夜查文献、做实验，我对夜间视力要求很高。了解到V5晶体的大光 区优势后，我非常心动。" 在发布会当天，王同学在深圳普瑞眼科完成了全套详细的术前检查。拿到合 格的检查报告后，他表示："检查流程非常细致，徐洋涛医生对数据的解 ...

进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为7084.28万元。该股近5个交易日累 计上涨4.01%，主力资金合计净流入6746.8万元。 责任编辑：小浪快报 1月9日，爱尔眼科收涨0.97%，收盘价为11.42元，发生1笔大宗交易，合计成交量22.1万股，成交金额 249.95万元。 第1笔成交价格为11.31元，成交22.10万股，成交金额249.95万元，溢价率为-0.96%，买方营业部为华泰 证券股份有限公司成都锦晖西二街证券营业部，卖方营业部为华泰证券股份有限公司成都锦晖西二街证 券营业部。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ ...

爱尔眼科1月9日大宗交易平台出现一笔成交，成交量22.10万股，成交金额249.95万元，大宗交易成交价 为11.31元，相对今日收盘价折价0.96%。该笔交易的买方营业部为华泰证券股份有限公司成都锦晖西二 街证券营业部，卖方营业部为华泰证券股份有限公司成都锦晖西二街证券营业部。 进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为7084.28万元。 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 22.10 | 249.95 | 11.31 | -0.96 | 华泰证券股份有限公司成 | 华泰证券股份有限公司成 | | | | | | 都锦晖西二街证券营业部 | 都锦晖西二街证券营业部 | （文章来源：证券时报网） 证券时报·数据宝统计显示，爱尔眼科今日收盘价为11.42元，上涨0.97%，日换手率为0.78%，成交额为 7.11亿元，全天主力资金净流入792.30万元， ...

证券日报网讯 1月8日，何氏眼科（301103）在互动平台回答投资者提问时表示，股价的波动受市场整 体情绪、行业板块轮动、资金偏好等多重因素综合影响。公司始终重视市值管理工作，坚持聚焦主业， 稳健经营，以投资者为本，通过不断完善公司治理、提升经营质量、合理规划现金分红、提高信息披露 和投资者关系管理水平，系统性推进市值管理工作，致力于实现公司内在价值与市场价值的动态平衡， 切实维护全体股东的长远利益。公司坚信，长期稳定的市值源于扎实的经营业绩与清晰的价值逻辑。未 来，公司坚持长期可持续发展战略、透明的信息披露与有效的投资者沟通，稳步推进资本市场品牌建 设，努力为投资者创造长期价值。 ...

证券日报网讯1月8日，何氏眼科（301103）在互动平台回答投资者提问时表示，公司管理层将根据公司 资金安排并结合实际经营情况及未来发展需求等多种因素考量，未来如有回购相关计划，将严格按照法 律法规及交易所规则，履行决策程序并及时披露相关信息。 ...

Group 1 - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan [1] - On January 8, 2026, the company will repurchase 60,000 shares at a cost of HKD 160,700 [1]

Group 1 - The company, Chaoyue Eye Care (02219), announced a share buyback plan [1] - On January 8, 2026, the company will repurchase 60,000 shares at a cost of HKD 160,700 [1]

Summary of Key Points Core Viewpoint - The company, Chaoyue Eye Care (02219.HK), announced a share buyback on January 8, 2023, spending HKD 160,000 to repurchase 60,000 shares at a price range of HKD 2.66 to HKD 2.69 per share [1] Group 1 - The total expenditure for the share buyback was HKD 160,000 [1] - The number of shares repurchased was 60,000 [1] - The price range for the repurchased shares was between HKD 2.66 and HKD 2.69 [1]